Claims for Patent: 8,288,130

Summary for Patent: 8,288,130

Title:	Polypeptide cleavage process
Abstract:	A palladate palladium-promoted hydrolytic polypeptide cleavage process which selectively cleaves the polypeptide at a Cys-His cleavage site comprising solubilizing the polypeptide in a reaction mixture comprised of a palladate palladium promoter dissolved in a high-concentration acidic organic acid solvent.
Inventor(s):	Seo; Jin Seog (Brampton, CA), Strydom; Daniel (Eagle, NE), Holmquist; Barton (Eagle, NE)
Assignee:	Medtronic, Inc. (Minneapolis, MN)
Application Number:	12/795,073
Patent Claims:	1. A palladium complex-promoted hydrolytic polypeptide cleavage process which selectively cleaves a polypeptide at a Cys-His cleavage site, comprising: solubilizing the polypeptide in a reaction mixture comprised of a palladium complex dissolved in a high-concentration organic acid solvent selected from the group consisting of acetic acid, propionic acid, butyric acid, pyruvic acid, lactic acid, tartaric acid, citric acid, oxalic acid, malic acid, maleic acid, malonic acid, fumaric acid, glutaric acid, adipoc acid, succinic acid, pimelic acid, tricarballylic acid, glucuronic acid, saccharic acid, and dicarboxylic acids, wherein the concentration of the organic solvent in the reaction mixture is from about 1 to about 22 molar, and wherein the cleavage occurs at the carboxamide bond between the histidine residue and the residue immediately adjacent to the histidine on the C-terminal side. 2. The process of claim 1, wherein the polypeptide is a recombinantly expressed chimeric protein in the form of an inclusion body and the molar ratio of palladium complex to inclusion body in the reaction mixture is from about 2:1 to about 20:1. 3. The process of claim 2, wherein the chimeric protein cleavage site includes a linker, which is adjacent to Cys. 4. The process of claim 3, wherein the linker is selected from the group consisting of DDDD (SEQ ID NO:9), DDDK (SEQ ID NO:10), DTRL (SEQ ID NO:11), and GGPR (SEQ ID NO:12). 5. The process of claim 1, wherein the reaction mixture temperature is maintained at about 50 .degree. C. to about 70 .degree. C. 6. The process of claim 1, wherein the cleavage reaction proceeds for 1 to 6 hours. 7. The process of claim 1, wherein the organic acid solvent is combined with one or more palladium complexes with ligands selected from the group consisting of ethylenediamine; propylenediamine; 2-aminomethyl pyridine; 2(2-aminoethyl) pyridine; 2(2-methylaminoethyl)pyridine; 2,2'-bypyridyl; 1,10-phenanthroline: 3-hydroxy-2(dimethylaminomethyl)pyridine; 3-hydroxy-1,5-dithiacyclooctane; 3,6-dithiaoctane-1,8-diol; 1,2-diphenylphosphineethane; triphenylphosphine; diphenylphosphineferrocene; and diethylenetriamine. 8. The process of claim 1, wherein the palladium promoter is a Palladium(II) complex selected from the group consisting of Na.sub.2PdCl.sub.4; cis-[Pd(en)Cl.sub.2]; cis-[Pd(bp)Cl.sub.2]; cis-[Pd(phen)Cl.sub.2]; cis-[Pd(pn)Cl.sub.2]; cis-[Pd(pic)Cl.sub.2]; cis-[Pd(dtco-OH)Cl.sub.2cis-[Pd(en)(OH.sub.2).sub.2].sup.2+, cis-[Pd(pn)(OH.sub.2).sub.2].sup.2+, cis-[Pd(pic)(OH.sub.2).sub.z].sup.2+, cis-[Pd(bp)(OH.sub.2).sub.2].sup.2+; cis-[Pd(phen)(OH.sub.2).sub.2].sup.2+; cis-(Pd(dtco-OH)(OH.sub.2).sub.2].sup.2+; and [Pd(OH.sub.2).sub.3(OH)](NO.sub.3). 9. The process of claims 1, wherein the palladium complex is tetrachloropalladate and the molar ratio of tetrachloropalladate to polypeptide is around 10:1. 10. The process of claim 1, wherein the organic solvent is combined with an inorganic acid selected from the group consisting of HCl, H.sub.3PO.sub.4, H.sub.2SO.sub.4, or HClO.sub.4. 11. The process of claim 1, wherein the organic acid solvent is selected from the group consisting of acetic acid, propionic acid, butyric acid, pyruvic acid, lactic acid, tartaric acid, citric acid, oxalic acid, malic acid, maleic acid, malonic acid, fumaric acid, glutaric acid, adipoc acid, succinic acid, pimelic acid, tricarballylic acid, glucuronic acid, and saccharic acid. 12. The process of claim 1, wherein the organic solvent is malonic acid. 13. The process of claim 1, wherein the organic solvent is 5 M malonic acid or 6 M malonic acid, and the palladium complex is tetrachloropalladate. 14. The process of claim 1, wherein the organic solvent is citric acid. 15. The process of claim 1, wherein the organic solvent is 3 M citric acid, the palladium complex is sodium tetrachloropalladate, and the reaction mixture comprises a palladate ligand selected from the group consisting of pic, methionine or histidine. 16. The process of claim 1, wherein the polypeptide, which comprises the Cys-His cleavage site, is a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide-2 (GLP-2), a parathyroid hormone (PTH), a growth hormone releasing hormone (GRF), a parathyroid hormone related protein, an adrenocorticotropic hormone (ACTH), an enkephalin, an endorphin, an exendin, an amylin, an opioid peptide, a gaegurin 5, a gaegurin 6, a brevinin 1, a ranatuerin selected from the group consisting of ranatuerin 1 through 9, an esculetin, a glucose-dependent insulinotropic polypeptide (GIP), a glucagon, a motilin, a thymopoietin, a thymosin, an ubiquitin, a serum thymic factor, a thymic humoral factor, a neurotensin, a tuftsin, a gastrin, a calcitonin, a luteinizing-hormone-releasing hormone, a pancreatic polypeptide, an endothelin, a corticotrophin releasing factor, a neuropeptide Y, an atrial naturetic peptide, a galanin, a somatostatin, a vasoactive intestinal peptide, or an insulin. 17. The process of claim 16, wherein the polypeptide is made synthetically. 18. The process of claims 16, wherein the polypeptide was expressed recombinantly in host cells and was recovered from the host cells in the form of an inclusion body. 19. The process of claim 18, wherein the host cells are Escherichia coli. 20. A peptide purification process comprising: (a) cleaving the polypeptide of the process of claim 1; and (b) recovering the cleaved polypeptide from step (a) by ultrafiltration, filtration or ion-exchange chromatography.

Details for Patent 8,288,130

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-24